Answers are grounded in this paper and cite their sources.
This review outlines the evolving therapeutic landscape for pulmonary arterial hypertension, highlighting both established pathway modulators and emerging pipeline drugs targeting vascular remodeling.
Research in pulmonary hypertension (PH) in general and in pulmonary arterial hypertension (PAH) in particular has been extremely active in the past few years. The current therapeutic landscape includes multiple compounds shown to be active in modulating and ameliorating the pathological changes in the endothelin, nitric oxide (NO), and prostacyclin pathways. In addition, development of new compounds targeting pathways of pulmonary vascular remodeling due to inflammation, fibrosis, and oxidative stress is underway. This review summarizes the most recent achievements and newly conducted clinical trials—some with novel trial design—for treatment of PH and PAH.
No takes yet. Share an insight, caveat, or question.
Ioana R. Preston (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: